Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accounts Payables (2020 - 2025)

Mirum Pharmaceuticals has reported Accounts Payables over the past 6 years, most recently at $9.6 million for Q4 2025.

  • Quarterly results put Accounts Payables at $9.6 million for Q4 2025, down 34.23% from a year ago — trailing twelve months through Dec 2025 was $9.6 million (down 34.23% YoY), and the annual figure for FY2025 was $9.6 million, down 34.23%.
  • Accounts Payables for Q4 2025 was $9.6 million at Mirum Pharmaceuticals, down from $12.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for MIRM hit a ceiling of $17.7 million in Q2 2025 and a floor of $4.9 million in Q1 2022.
  • Median Accounts Payables over the past 5 years was $9.4 million (2021), compared with a mean of $9.7 million.
  • Biggest five-year swings in Accounts Payables: surged 190.89% in 2021 and later crashed 34.23% in 2025.
  • Mirum Pharmaceuticals' Accounts Payables stood at $9.2 million in 2021, then decreased by 5.19% to $8.7 million in 2022, then dropped by 14.66% to $7.4 million in 2023, then soared by 97.11% to $14.6 million in 2024, then crashed by 34.23% to $9.6 million in 2025.
  • The last three reported values for Accounts Payables were $9.6 million (Q4 2025), $12.2 million (Q3 2025), and $17.7 million (Q2 2025) per Business Quant data.